Appointments: Top-Level Changes At J&J, Roche, Pierre Fabre, Nordic Nanovector, Inthera And DDF

Johnson & Johnson group worldwide chairman Sandra Peterson is leaving the business, effective Oct. 1, after more than five years with the company. Peterson, who reports to CEO and chair of the board of directors Alex Gorsky, was hired in 2012, primarily with the task of turning around J&J's Consumer business, and addressing IT and supply-chain issues. She also oversees the group's medical device business. Before that she was chairman & CEO of Bayer CropScience AG in Germany, and previously served as CEO of Bayer Medical Care and president of Bayer HealthCare AG’s Diabetes Care Division. To help with the transition, J&J is making a series of additional leadership changes, all effective from July 2: Joaquin Duato, executive vice president, worldwide chairman, pharmaceuticals, and Paul Stoffels, executive vice president, chief scientific officer of Johnson & Johnson, have been appointed to the position of vice chairman of the executive committee. Duato will be responsible for the pharmaceuticals and consumer sectors, as well as supply chain, IT, global services, and the health and wellness businesses. Stoffels will be responsible for pharmaceutical research & development, global public health, the office of the chief medical officer, external innovation, pharmaceuticals business development and healthcare technology. Other promotions are: Ashley McEvoy to executive vice president, worldwide chairman, medical devices; Jennifer Taubert as executive vice president, worldwide chairman, pharmaceuticals; Kathy Wengel as executive vice president, chief global supply chain officer; and Michael Sneed as executive vice president, global corporate affairs and chief communication officer.